Results 1 to 10 of about 3,069 (165)
A Traveling Mission: Albert E. Kahn in the USSR [PDF]
Литература двух АмерикThe paper is devoted to an episode of Soviet-American cultural and literary relations at the turn of the 1950s–1960s, connected with American writer and journalist Albert Eugene Kahn (1912–1979). The article reconstructs the history of his Soviet travels Olga Yu. Panovadoaj +2 more sourcesThe Archives of the Planet: The Life and Works of Albert Kahn
Visual Anthropology, 2015 Surrounded by a beautiful garden, the Albert Kahn museum in Paris houses the most important collection of autochromes in the world. This corpus, known as The Archives of the Planet, was created by Albert Kahn, a wealthy French banker who, during and after World War I, ran the project to collect visual documents (photographs and films) about small ...Jean-François Wernerexaly +3 more sourcesPrognostic predictions in psychosis: exploring the complementary role of machine learning models [PDF]
BMJ Mental HealthBackground Predicting outcomes in schizophrenia spectrum disorders is challenging due to the variability of individual trajectories. While machine learning (ML) shows promise in outcome prediction, it has not yet been integrated into clinical practice ...Metten Somers, Hugo G Schnack, Rene S Kahn, Diane F van Rappard, Frank L Gerritse, Edwin van Dellen, Violet van Dee, Seyed M Kia, Caterina Fregosi, Wilma E Swildens, Anne Alkema, Albert Batalla, Coen van den Berg, Danko Coric, Lotte G Dijkstra, Arthur van den Doel, Livia S Dominicus, John Enterman, Marte Z van der Horst, Fedor van Houwelingen, Charlotte S Koch, Lisanne E M Koomen, Marjan Kromkamp, Michelle Lancee, Brian E Mouthaan, Eline J Regeer, Raymond W J Salet, Jorgen Straalman, Marjolein H T de Vette, Judith Voogt, Inge Winter-van Rossum, Wiepke Cahn +31 moredoaj +2 more sourcesDigital health technologies in the accelerating medicines Partnership® Schizophrenia Program [PDF]
SchizophreniaAlthough meta-analytic studies have shown that 25-33% of those at Clinical High Risk (CHR) for psychosis transition to a first episode of psychosis within three years, less is known about estimating the risk of transition at an individual level.Johanna T. W. Wigman, Ann Ee Ching, Yoonho Chung, Habiballah Rahimi Eichi, Erlend Lane, Carsten Langholm, Aditya Vaidyam, Andrew Jin Soo Byun, Anastasia Haidar, Jessica Hartmann, Angela Nunez, Dominic Dwyer, Adibah Amani Nasarudin, Owen Borders, Isabelle Scott, Zailyn Tamayo, Priya Matneja, Kang-Ik Cho, Jean Addington, Luis K. Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M. Corcoran, Barbara A. Cornblatt, Covadonga M. Diaz-Caneja, Lauren M. Ellman, Paolo Fusar-Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri S. Keshavan, Sung-Wan Kim, Nikolaos Koutsouleris, Kerstin Langbein, Daniel Mamah, Daniel H. Mathalon, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesus Perez, Diana O. Perkins, Albert R. Powers, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, Walid Yassin, William S. Stone, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Jijun Wang, Daniel H. Wolf, Phillip Wolff, Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), Laura M. Rowland, Simon D’Alfonso, Ofer Pasternak, Sylvain Bouix, Patrick D. McGorry, Rene S. Kahn, John M. Kane, Carrie E. Bearden, Scott W. Woods, Martha E. Shenton, Barnaby Nelson, Justin T. Baker, John Torous +80 moredoaj +2 more sourcesCollecting language, speech acoustics, and facial expression to predict psychosis and other clinical outcomes: strategies from the AMP® SCZ initiative [PDF]
SchizophreniaSpeech-based detection of early psychosis is progressing at a rapid pace. Within this evolving field, the Accelerating Medicines Partnership® in Schizophrenia (AMP® SCZ) is uniquely positioned to deepen our understanding of how language and related ...Zarina R. Bilgrami, Eduardo Castro, Carla Agurto, Einat Liebenthal, Michaela Ennis, Justin T. Baker, Isabelle Scott, Beau-Luke Colton, Kang Ik K. Cho, Linying Li, Zailyn Tamayo, Mara Henecks, Habiballah Rahimi Eichi, Tae’lar Henry, Jean Addington, Luis K. Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Barbara A. Cornblatt, Lauren M. Ellman, Paolo Fusar-Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri S. Keshavan, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Covadonga M. Diaz-Caneja, Daniel H. Mathalon, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesus Perez, Diana O. Perkins, Albert R. Powers, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Walid Yassin, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Jijun Wang, Daniel H. Wolf, Patrick D. McGorry, Rene S. Kahn, John M. Kane, Alan Anticevic, Carrie E. Bearden, Dominic Dwyer, Tashrif Billah, Sylvain Bouix, Ofer Pasternak, Martha E. Shenton, Scott W. Woods, Barnaby Nelson, Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), Guillermo A. Cecchi, Cheryl M. Corcoran, Phillip M. Wolff +77 moredoaj +2 more sourcesSample ascertainment and clinical outcome measures in the Accelerating Medicines Partnership® Schizophrenia Program [PDF]
SchizophreniaClinical ascertainment and clinical outcome are key features of any large multisite study. In the ProNET and PRESCIENT research networks, the Accelerating Medicines Partnership® Schizophrenia (AMP®SCZ) Clinical Ascertainment and Outcome Measures Team ...Jean Addington, Lu Liu, Amy Braun, Andrea Auther, Monica E. Calkins, Barbara A. Cornblatt, Cheryl M. Corcoran, Paolo Fusar-Poli, Melissa J. Kerr, Catalina V. Mourgues-Codern, Angela R. Nunez, Dominic Oliver, Gregory P. Strauss, Barbara C. Walsh, Luis K. Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Ricardo E. Carrion, Eric Yu Hai Chen, Jimmy Choi, Michael J. Coleman, Philippe Conus, Covadonga M. Diaz-Caneja, Dominic Dwyer, Lauren M. Ellman, Masoomeh Faghankhani, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Hui, Grace R. Jacobs, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri S. Keshavan, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Kathryn E. Lewandowski, Daniel Mamah, Patricia J. Marcy, Daniel H. Mathalon, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Nora Penzel, Jesus Perez, Diana O. Perkins, Albert R. Powers, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Andrew Thompson, Judy L. Thompson, Rachel Upthegrove, Swapna Verma, Jijun Wang, Heather M. Wastler, Alana Wickham, Inge Winter-van Rossum, Daniel H. Wolf, Sylvain Bouix, Ofer Pasternak, Rene S. Kahn, Carrie E. Bearden, John M. Kane, Patrick D. McGorry, Kate Buccilli, Barnaby Nelson, Martha E. Shenton, Scott W. Woods, the Accelerating Medicines Partnership® -Schizophrenia, Alison R. Yung +79 moredoaj +2 more sourcesThe MR neuroimaging protocol for the Accelerating Medicines Partnership® Schizophrenia Program [PDF]
SchizophreniaNeuroimaging with MRI has been a frequent component of studies of individuals at clinical high risk (CHR) for developing psychosis, with goals of understanding potential brain regions and systems impacted in the CHR state and identifying prognostic or ...Michael P. Harms, Kang-Ik K. Cho, Alan Anticevic, Nicolas R. Bolo, Sylvain Bouix, Dylan Campbell, Tyrone D. Cannon, Guillermo Cecchi, Mathias Goncalves, Anastasia Haidar, Dylan E. Hughes, Igor Izyurov, Omar John, Tina Kapur, Nicholas Kim, Elana Kotler, Marek Kubicki, Joshua M. Kuperman, Kristen Laulette, Ulrich Lindberg, Christopher Markiewicz, Lipeng Ning, Russell A. Poldrack, Yogesh Rathi, Paul A. Romo, Zailyn Tamayo, Cassandra Wannan, Alana Wickham, Walid Yassin, Juan Helen Zhou, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M. Corcoran, Barbara A. Cornblatt, Covadonga M. Diaz-Caneja, Lauren M. Ellman, Paolo Fusar-Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri S. Keshavan, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Daniel H. Mathalon, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesus Perez, Diana O. Perkins, Albert R. Powers, Jack Rogers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Judy L. Thompson, Rachel Upthegrove, Swapna K. Verma, Jijun Wang, Daniel H. Wolf, Rene S. Kahn, John M. Kane, Patrick D. McGorry, Barnaby Nelson, Scott W. Woods, Martha E. Shenton, Stephen J. Wood, Carrie E. Bearden, Accelerating Medicines Partnership® Schizophrenia (AMP® SCZ), Ofer Pasternak +87 moredoaj +2 more sourcesThe electroencephalography protocol for the Accelerating Medicines Partnership® Schizophrenia Program: Reliability and stability of measures [PDF]
SchizophreniaIndividuals at clinical high risk for psychosis (CHR) have variable clinical outcomes and low conversion rates, limiting development of novel and personalized treatments.Daniel H. Mathalon, Spero Nicholas, Brian J. Roach, Tashrif Billah, Suzie Lavoie, Thomas Whitford, Holly K. Hamilton, Lauren Addamo, Andrey Anohkin, Tristan Bekinschtein, Aysenil Belger, Kate Buccilli, John Cahill, Ricardo E. Carrión, Stefano Damiani, Ilvana Dzafic, Bjørn H. Ebdrup, Igor Izyurov, Johanna Jarcho, Raoul Jenni, Anna Jo, Sarah Kerins, Clarice Lee, Elizabeth A. Martin, Rocio Mayol-Troncoso, Margaret A. Niznikiewicz, Muhammad Parvaz, Oliver Pogarell, Julio Prieto-Montalvo, Rachel Rabin, David R. Roalf, Jack Rogers, Dean F. Salisbury, Riaz Shaik, Stewart Shankman, Michael C. Stevens, Yi Nam Suen, Nicole C. Swann, Xiaochen Tang, Judy L. Thompson, Ivy Tso, Julian Wenzel, Juan Helen Zhou, Jean Addington, Luis Alameda, Celso Arango, Nicholas J. K. Breitborde, Matthew R. Broome, Kristin S. Cadenhead, Monica E. Calkins, Rolando I. Castillo-Passi, Eric Yu Hai Chen, Jimmy Choi, Philippe Conus, Cheryl M. Corcoran, Barbara A. Cornblatt, Covadonga M. Diaz-Caneja, Lauren M. Ellman, Paolo Fusar-Poli, Pablo A. Gaspar, Carla Gerber, Louise Birkedal Glenthøj, Leslie E. Horton, Christy Lai Ming Hui, Joseph Kambeitz, Lana Kambeitz-Ilankovic, Matcheri S. Keshavan, Minah Kim, Sung-Wan Kim, Nikolaos Koutsouleris, Jun Soo Kwon, Kerstin Langbein, Daniel Mamah, Vijay A. Mittal, Merete Nordentoft, Godfrey D. Pearlson, Jesus Perez, Diana O. Perkins, Albert R. Powers, Fred W. Sabb, Jason Schiffman, Jai L. Shah, Steven M. Silverstein, Stefan Smesny, William S. Stone, Gregory P. Strauss, Rachel Upthegrove, Swapna K. Verma, Jijun Wang, Daniel H. Wolf, Tianhong Zhang, Sylvain Bouix, Ofer Pasternak, Kang-Ik K. Cho, Michael J. Coleman, Dominic Dwyer, Angela Nunez, Zailyn Tamayo, Stephen J. Wood, Rene S. Kahn, John M. Kane, Patrick D. McGorry, Carrie E. Bearden, Barnaby Nelson, Scott W. Woods, Martha E. Shenton, Accelerating Medicines Partnership® Schizophrenia Program, Gregory A. Light +107 moredoaj +2 more sources
